We hope that the implementation of a new model of care for acute low back pain will make an enormous difference to the health outcomes of patients when visiting an emergency department (ED) and improve the quality of emergency services.
The SHaPED trial aims to improve ED practices through implementing an evidence-based model of care for acute low back pain and evaluating the effects on healthcare services, patient outcomes, and cost compared with usual emergency care. Low back pain patients presenting to EDs often receive complex and unnecessary interventions (e.g. imaging and opioids) yet miss out on the basics of care such as advice on how to self-manage the condition. The Agency for Clinical Innovation (ACI) has recently published a model of care for acute low back pain. The key messages for practice are that non-serious acute low back pain does not require imaging, simple analgesics should be the first option for medicine, and patients should be managed as outpatients. Timely referral and scheduled follow-up reviews are also recommended. At present, active implementation of the ACI model of care and its effects have not been evaluated, and passive dissemination (i.e. publication on a website) is unlikely to change ED practices.
This project is no longer recruiting.
Principal Investigator: Professor Chris Maher (IMH)
Chief Investigators: Dr Gustavo Machado (IMH), Dr Bethan Richards (IMH), Dr Chris Needs (SLHD), Dr James Edwards (SLHD), Dr Eileen Rogan (SLHD), Dr Rochelle Facer (SLHD), Dr David Lord Cowell (ISHLD), Professor Ian Harris (IMH), Professor Rachelle Buchbinder (Monash University), Ms Danielle Coombs (IMH), Associate Professor Laurent Billot (University of Sydney), Professor Kirsten Howard (University of Sydney) and Professor Kirsten McCaffery (University of Sydney).
For more information about this project, please visit the SHaPED Trial Website or contact Dr Gustavo Machado. The project has received ethics approval from Sydney Local Health District, is funded by Sydney Health Partners, and is endorsed by the Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network.